Glioblastoma multiforme (GBM) is one of the most common human brain tumors. Recent discoveries show that GBMs arise from the transformation of adult neural stem cells, defined glioma stem cell (GSC) characterized by self-renewal, long-term proliferation and ability to differentiate. GSCs are the main responsible for the origin, maintenance and progression of the neoplasm. As consequence effective therapies should target GSCs. A promising new approach for the treatment of malignant glioma is the engineering of novel oncolytic Herpes Simplex Virus (oHSV) vectors for transferring therapeutic genes, based on their ability to tailor virus replication to tumor cells. The field of oHSV therapy for treatment of glioblastoma continues to evolve with the discovery of new tumor-specific targets to be engineered into such vectors.
This Research Topic will focus on: i) GBM classification, ii) Glioma stem cells and related therapies, iii) oncolytic vectors as a potential alternative for treating this tumor
Glioblastoma multiforme (GBM) is one of the most common human brain tumors. Recent discoveries show that GBMs arise from the transformation of adult neural stem cells, defined glioma stem cell (GSC) characterized by self-renewal, long-term proliferation and ability to differentiate. GSCs are the main responsible for the origin, maintenance and progression of the neoplasm. As consequence effective therapies should target GSCs. A promising new approach for the treatment of malignant glioma is the engineering of novel oncolytic Herpes Simplex Virus (oHSV) vectors for transferring therapeutic genes, based on their ability to tailor virus replication to tumor cells. The field of oHSV therapy for treatment of glioblastoma continues to evolve with the discovery of new tumor-specific targets to be engineered into such vectors.
This Research Topic will focus on: i) GBM classification, ii) Glioma stem cells and related therapies, iii) oncolytic vectors as a potential alternative for treating this tumor
